Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Scios Nova-Genentech deal leaves analysts divided

Scios Nova-Genentech deal leaves analysts divided

The deal between Scios Nova Inc. and Genentech Inc. covering SCIO's Auriculin left Wall Street analysts divided last week over the relative benefits of the deal to each side. Although SCIO shares closed the week up $1.375 at $8, analysts on balance rated the deal better for GNE than for SCIO.

SCIO (Mountain View, Calif.) and GNE agreed to collaborate to complete the development of SCIO's Auriculin atrial natriuretic peptide to treat acute renal failure (ARF) in

Read the full 845 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE